This post was originally published on this site

Equities research analysts expect 10x Genomics, Inc. (NASDAQ:TXG) to post earnings per share (EPS) of ($0.28) for the current quarter, according to Zacks Investment Research. Three analysts have made estimates for 10x Genomics’ earnings. The lowest EPS estimate is ($0.44) and the highest is ($0.16). 10x Genomics reported earnings per share of ($0.07) in the same quarter last year, which suggests a negative year over year growth rate of 300%. The firm is expected to announce its next earnings results after the market closes on Wednesday, February 17th.

On average, analysts expect that 10x Genomics will report full-year earnings of ($1.56) per share for the current financial year, with EPS estimates ranging from ($1.73) to ($1.43). For the next year, analysts expect that the firm will post earnings of ($0.50) per share, with EPS estimates ranging from ($0.79) to ($0.31). Zacks’ EPS averages are a mean average based on a survey of research firms that cover 10x Genomics.

10x Genomics (NASDAQ:TXG) last announced its quarterly earnings data on Tuesday, November 10th. The company reported ($0.33) earnings per share for the quarter, hitting the consensus estimate of ($0.33). 10x Genomics had a negative return on equity of 19.98% and a negative net margin of 51.27%. The business had revenue of $71.82 million during the quarter, compared to the consensus estimate of $62.71 million.

A number of equities research analysts have recently weighed in on TXG shares. Zacks Investment Research downgraded shares of 10x Genomics from a “buy” rating to a “hold” rating in a research note on Friday, February 5th. Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell boosted their target price on shares of 10x Genomics from $165.00 to $195.00 in a research note on Wednesday, December 16th. Smith Barney Citigroup upped their price target on shares of 10x Genomics from $165.00 to $195.00 in a report on Wednesday, December 16th. The Goldman Sachs Group initiated coverage on 10x Genomics in a research report on Wednesday, December 2nd. They set a “neutral” rating and a $150.00 price objective on the stock. Finally, Morgan Stanley increased their target price on 10x Genomics from $135.00 to $145.00 and gave the company an “overweight” rating in a research report on Wednesday, November 11th. Two analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $141.18.

In other news, CEO Serge Saxonov sold 10,000 shares of the company’s stock in a transaction on Tuesday, December 1st. The shares were sold at an average price of $151.40, for a total value of $1,514,000.00. Following the sale, the chief executive officer now directly owns 973,431 shares of the company’s stock, valued at approximately $147,377,453.40. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Benjamin J. Hindson sold 33,750 shares of the stock in a transaction on Monday, February 1st. The stock was sold at an average price of $175.98, for a total transaction of $5,939,325.00. Following the sale, the insider now owns 69,686 shares of the company’s stock, valued at $12,263,342.28. The disclosure for this sale can be found here. Insiders sold a total of 176,250 shares of company stock worth $27,417,988 in the last quarter. Corporate insiders own 13.28% of the company’s stock.

Several hedge funds have recently bought and sold shares of the company. Stifel Financial Corp acquired a new stake in shares of 10x Genomics during the 4th quarter worth approximately $981,000. Laurion Capital Management LP increased its stake in 10x Genomics by 240.4% in the fourth quarter. Laurion Capital Management LP now owns 34,042 shares of the company’s stock valued at $4,820,000 after purchasing an additional 24,042 shares in the last quarter. Caisse DE Depot ET Placement DU Quebec acquired a new position in shares of 10x Genomics during the fourth quarter valued at about $5,268,000. Bamco Inc. NY boosted its position in shares of 10x Genomics by 22.6% during the 4th quarter. Bamco Inc. NY now owns 596,882 shares of the company’s stock worth $84,518,000 after purchasing an additional 109,845 shares in the last quarter. Finally, CWM Advisors LLC acquired a new stake in shares of 10x Genomics in the 4th quarter valued at about $322,000. 68.84% of the stock is owned by hedge funds and other institutional investors.

10x Genomics stock traded up $6.74 during midday trading on Friday, reaching $196.86. The company’s stock had a trading volume of 507,157 shares, compared to its average volume of 758,877. The stock has a market cap of $19.76 billion, a PE ratio of -145.82 and a beta of 1.39. 10x Genomics has a 52 week low of $48.78 and a 52 week high of $198.00. The business has a 50-day moving average price of $167.71 and a 200-day moving average price of $151.04.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. Its company offers chromium instruments, enzymes, microfluidic chips, slides, reagents, and other consumable products.

See Also: How dollar cost averaging works

Get a free copy of the Zacks research report on 10x Genomics (TXG)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for 10x Genomics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for 10x Genomics and related companies with MarketBeat.com’s FREE daily email newsletter.